Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AR C124910XX

Known as: AR-C124910XX 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Adenosine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
BACKGROUND The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
Does morphine administration affect ticagrelor conversion to its active metabolite in patients with acute myocardial infarction? A sub-analysis of the randomized, double-blind, placebo- -controlled…
Background. Therapy with aspirin and one of the platelet P2Y12 receptor inhibitors, preferably ticagrelor or prasugrel, is the… Expand
  • table 1
  • figure 1
  • figure 2
Highly Cited
2015
Highly Cited
2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective…
OBJECTIVES The goal of this study was to assess the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of escalating… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2015
2015
Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study
ObjectiveThe objective of this study was to assess the pharmacokinetic and pharmacodynamic behavior of ticagrelor administered… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
2012
2012
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects
PurposeTicagrelor, a reversibly binding oral P2Y12 receptor antagonist, is predominantly metabolized by cytochrome P450 3A and… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
2012
2012
Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers
What is known and Objective:  Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist and has been approved in… Expand
2011
2011
Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS.
Ticagrelor is the first direct acting reversibly binding oral platelet P2Y(12) receptor antagonist. The parent molecule and the… Expand
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 2
Highly Cited
2010
Highly Cited
2010
Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects
Ticagrelor [(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorophenyl) cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2010
Highly Cited
2010
Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry.
Rapid and sensitive analytical methods using liquid chromatography with tandem mass spectrometry (LC/MS/MS) were developed for… Expand
Highly Cited
2009
Highly Cited
2009
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
  • R. Teng, K. Butler
  • European Journal of Clinical Pharmacology
  • 2009
    • Corpus ID: 23490203
PurposeTicagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist in development for reduction of… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE